Ligand Pharmaceuticals (LGND) Other Accumulated Expenses (2014 - 2026)

Ligand Pharmaceuticals (LGND) has 8 years of Other Accumulated Expenses data on file, last reported at $300000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $300000.0 (changed N/A YoY), and the FY2025 full-year result was $135000.0, down 89.63% from the prior year.
• Other Accumulated Expenses advanced to $300000.0 in Q1 2026, from $135000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q4 2024 to a low of $135000.0 in Q3 2025.
• A 5-year average of $527571.4 and a median of $448000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 89.63% in 2025, while the deepest fall reached 89.63% in 2025.
• Tracing LGND's Other Accumulated Expenses over 5 years: stood at $457000.0 in 2022, then soared by 100.44% to $916000.0 in 2023, then soared by 42.14% to $1.3 million in 2024, then slumped by 89.63% to $135000.0 in 2025, then soared by 122.22% to $300000.0 in 2026.
• Business Quant data shows LGND's Other Accumulated Expenses at $300000.0 in Q1 2026, $135000.0 in Q4 2025, and $135000.0 in Q3 2025.